A Comparative Study on the effectiveness and Tolerability of Mirabegron and Antimuscarinics in the treatment of Overactive bladder

Background: Despite antimuscarinic treatment options being available as the first line agents for overactive bladder (OAB), there is still a need for distinct treatment approaches to manage its suboptimal response and noncompliance. Mirabegron, a β3-adrenoceptor agonist, could be a better alternativ...

Full description

Saved in:
Bibliographic Details
Published in:Research journal of pharmacy and technology 2023-05, Vol.16 (5), p.2369-2374
Main Authors: Jose, Sruthy, VP, Anukrishna, K Ajayan, Aarcha, Gopi, Malavika, Rajendran, Rohan, Vijayan, Meenu
Format: Article
Language:English
Subjects:
Bladder
Comorbidity
Drugs
Nocturia
Observational studies
Patients
Questionnaires
Statistical analysis
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Despite antimuscarinic treatment options being available as the first line agents for overactive bladder (OAB), there is still a need for distinct treatment approaches to manage its suboptimal response and noncompliance. Mirabegron, a β3-adrenoceptor agonist, could be a better alternative to antimuscarinics in OAB treatment with a good effectiveness/tolerability balance. Aim: To compare the clinical profile of mirabegron and antimuscarinics in the treatment of overactive bladder. Method: A prospective, observational study was conducted in two groups of patients who received either mirabegron (n=120) or antimuscarinics (n=120) for the treatment of OAB. Effectiveness of the drugs were assessed at baseline, 4 and 8 weeks after the treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostatic Symptom Score (IPSS) questionnaires. The safety assessment was done by measuring the post-void residual (PVR) urine volume and assessing the adverse drug reactions (ADR). The probability and severity of the ADRs were measured using Naranjo scale and Hartwig’s scale respectively. Also a subgroup analysis was carried out to compare the effectiveness of the two drugs in patients with OAB related to benign prostatic hyperplasia (BPH). Results: The overall effectiveness of antimuscarinics and mirabegron was found to be similar, but mirabegron showed better reduction in the daytime frequency (p=0.049). They also differ in safety profile with the overall incidence of adverse events being significantly higher in antimuscarinics group (15.83%) (19/120) than in the mirabegron group group (1.7%) (2/120) (p
ISSN:0974-3618
0974-360X
0974-306X
DOI:10.52711/0974-360X.2023.00390